Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?

Key Takeaways RXRX dropped REC-994, REC-2282 and REC-3964 due to poor mid-stage study results and low efficacy. The company is now focused on REC-4881, which showed a 43% polyp reduction in early phase II data. RXRX is advancing REC-1245, REC-617, and REC-3565 as it refines its AI-driven drug development pipeline.Recursion Pharmaceuticals (RXRX) faced a massive setback in May 2025 after announcing the discontinuation of three key drug candidates — REC-994, REC-2282 and REC-3964 — due to disappointing resu ...